Colorectal Cancer | Specialty

Panitumumab Improves OS Versus Supportive Care in Phase III mCRC Trial

June 19th 2015

Patients with chemorefractory KRAS wild-type metastatic colorectal cancer had a statistically significant improvement in overall survival when treated with panitumumab (Vectibix) versus best supportive care, according to data released from a phase IlI study.

Selective Internal Radiation Therapy Effective in Some Patients With mCRC

June 12th 2015

Adding liver-direceted Yttrium-90 resin microspheres to frontline FOLFOX-based chemotherapy improved liver-specific progression-free survival by 7.9 months for patients with colorectal cancer with liver-dominant metastases.

Dr. Goldberg on PD-1 Blockade in Tumors with Mismatch Repair Deficiency

June 12th 2015

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

Triplet Therapy Effective in BRAF-mutant mCRC

June 8th 2015

The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.

Mayer Highlights the Potential of TAS-102 in CRC

June 8th 2015

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

June 5th 2015

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Mismatch Repair a Potential Biomarker for PD-1 Inhibition

May 29th 2015

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

Tabernero Discusses Novel Antibody Mixture Sym004 and Emerging Trends in Colorectal Cancer

May 18th 2015

Josep Tabernero, MD, PhD, discusses the potential of the antibody mixture Sym004 in mCRC, as well as other emerging trends in the management of colorectal cancer.

Fuchs Discusses Impact of Ramucirumab Approval in mCRC

May 15th 2015

Charles S. Fuchs, MD, discusses the impact of the approval of ramucirumab in metastatic colorectal cancer and what further research is needed for the optimal utilization of the VEGFR-2 inhibitor.

TAS-102 Improves Survival in Refractory mCRC

May 15th 2015

Treatment with the oral nucleoside TAS-102 (tipiracil hydrochloride) demonstrated a significant improvement in overall survival compared with placebo for patients with refractory metastatic colorectal cancer.

Dr. Andrew Chan on Aspirin's Link to Reduced Cancer Risk

May 4th 2015

Andrew T. Chan, MD, MPH, a research fellow in the Department of Nutrition at the Harvard School of Public Health, discusses the impact of aspirin of cancer risk.

Ramucirumab Approval Expanded, Breakthrough Designation for Crizotinib, and More

May 2nd 2015

FDA Approves Second-Line Ramucirumab for mCRC

April 24th 2015

The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer (mCRC) following progression an upfront bevacizumab-containing regimen.

Long-term Aspirin Use Decreases Risk of GI Cancers, Especially Colorectal

April 20th 2015

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

Oral Fluoropyrimidine TAS-102 in Refractory mCRC

April 16th 2015

Use of Regorafenib in Refractory mCRC

April 16th 2015

Second-Line Therapy for RAS Wild-Type mCRC

April 16th 2015

Choosing Between VEGF and EGFR Targeted Therapy in mCRC

April 16th 2015

Newly Diagnosed mCRC Treatment Goals

April 16th 2015

Dr. James Fleshman on Minimally Invasive Surgery for Colorectal Cancer

April 8th 2015

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.